Logo
x

Search category

Subscribe Now

P-III

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

  • March 15, 2022
UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis

  • November 22, 2021
Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

  • November 19, 2021
Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabetes in the US

Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabet...

  • November 17, 2021
Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

  • November 17, 2021
Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab)...

  • November 10, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.